0	8	Retinoic	retinoic	JJ
9	21	acid-induced	acid-induced	JJ
22	32	expression	expression	NN
33	35	of	of	IN
36	40	CD38	cd38	NN
41	48	antigen	antigen	NN
49	51	in	in	IN
52	59	myeloid	myeloid	JJ
60	65	cells	cell	NNS
66	68	is	be	VBZ
69	77	mediated	mediate	VBN
78	85	through	through	IN
86	94	retinoic	retinoic	JJ
95	99	acid	acid	NN
100	114	receptor-alpha	receptor-alpha	NN
114	115	.	.	.

117	121	CD38	cd38	NN
122	124	is	be	VBZ
125	126	a	a	DT
127	136	leukocyte	leukocyte	NN
137	152	differentiation	differentiation	NN
153	160	antigen	antigen	NN
161	165	that	that	WDT
166	169	has	have	VBZ
170	174	been	be	VBN
175	182	thought	think	VBN
183	185	to	to	TO
186	188	be	be	VB
189	190	a	a	DT
191	201	phenotypic	phenotypic	JJ
202	208	marker	marker	NN
209	211	of	of	IN
212	221	different	different	JJ
222	236	subpopulations	subpopulation	NNS
237	239	of	of	IN
240	242	T-	T-	NNP
243	246	and	and	CC
247	249	B-	b-	NN
250	261	lymphocytes	lymphocyte	NNS
261	262	.	.	.

263	265	In	in	IN
266	273	myeloid	myeloid	JJ
274	279	cells	cell	NNS
279	280	,	,	,
281	285	CD38	cd38	NN
286	288	is	be	VBZ
289	298	expressed	express	VBN
299	305	during	during	IN
306	311	early	early	JJ
312	318	stages	stage	NNS
319	321	of	of	IN
322	337	differentiation	differentiation	NN
337	338	.	.	.

339	348	Virtually	virtually	RB
349	351	no	no	DT
352	363	information	information	NN
364	366	is	be	VBZ
367	376	available	available	JJ
377	379	on	on	IN
380	390	regulation	regulation	NN
391	394	and	and	CC
395	404	functions	function	NNS
405	407	of	of	IN
408	412	CD38	cd38	NN
412	413	.	.	.

414	422	Recently	recently	RB
423	425	we	we	PRP
426	434	reported	report	VBD
435	439	that	that	IN
440	458	all-trans-retinoic	all-trans-retinoic	JJ
459	463	acid	acid	NN
464	465	(	(	(
465	469	ATRA	ATRA	NNP
469	470	)	)	)
471	473	is	be	VBZ
474	475	a	a	DT
476	482	potent	potent	JJ
483	486	and	and	CC
487	493	highly	highly	RB
494	502	specific	specific	JJ
503	510	inducer	inducer	NN
511	513	of	of	IN
514	518	CD38	cd38	NN
519	529	expression	expression	NN
530	532	in	in	IN
533	538	human	human	JJ
539	552	promyelocytic	promyelocytic	JJ
553	561	leukemia	leukemia	NN
562	567	cells	cell	NNS
567	568	.	.	.

569	573	Here	here	RB
574	576	we	we	PRP
577	583	report	report	VBP
584	588	that	that	IN
589	601	ATRA-induced	atra-induced	JJ
602	612	expression	expression	NN
613	615	of	of	IN
616	620	CD38	cd38	NN
621	628	antigen	antigen	NN
629	631	in	in	IN
632	639	myeloid	myeloid	JJ
640	645	cells	cell	NNS
646	648	is	be	VBZ
649	657	mediated	mediate	VBN
658	665	through	through	IN
666	674	retinoic	retinoic	JJ
675	685	acid-alpha	acid-alpha	NN
686	694	receptor	receptor	NN
695	696	(	(	(
696	699	RAR	RAR	NNP
700	705	alpha	alpha	NN
705	706	)	)	)
706	707	.	.	.

708	712	ATRA	ATRA	NNP
713	719	failed	fail	VBD
720	722	to	to	TO
723	729	induce	induce	VB
730	734	CD38	cd38	NN
735	745	expression	expression	NN
746	748	in	in	IN
749	750	a	a	DT
751	757	mutant	mutant	JJ
758	766	subclone	subclone	NN
767	769	of	of	IN
770	773	the	the	DT
774	779	HL-60	HL-60	NNP
780	787	myeloid	myeloid	JJ
788	796	leukemia	leukemia	NN
797	801	cell	cell	NN
802	806	line	line	NN
807	808	(	(	(
808	818	designated	designate	VBN
819	825	HL-60R	HL-60R	NNP
825	826	)	)	)
827	831	that	that	WDT
832	834	is	be	VBZ
835	845	relatively	relatively	RB
846	855	resistant	resistant	JJ
856	858	to	to	TO
859	871	ATRA-induced	atra-induced	JJ
872	884	granulocytic	granulocytic	JJ
885	900	differentiation	differentiation	NN
900	901	.	.	.

902	912	Retroviral	retroviral	JJ
913	928	vector-mediated	vector-mediated	JJ
929	941	transduction	transduction	NN
942	944	of	of	IN
945	947	RA	RA	NNP
948	956	receptor	receptor	NN
957	958	(	(	(
958	961	RAR	RAR	NNP
962	967	alpha	alpha	NN
967	968	)	)	)
969	973	into	into	IN
974	978	this	this	DT
979	985	HL-60R	HL-60R	NNP
986	994	subclone	subclone	NN
995	1005	completely	completely	RB
1006	1014	restored	restore	VBD
1015	1018	the	the	DT
1019	1030	sensitivity	sensitivity	NN
1031	1033	of	of	IN
1034	1039	these	these	DT
1040	1045	cells	cell	NNS
1046	1048	to	to	TO
1049	1053	ATRA	ATRA	NNP
1054	1056	in	in	IN
1057	1062	terms	term	NNS
1063	1065	of	of	IN
1066	1071	their	their	PRP$
1072	1079	ability	ability	NN
1080	1082	to	to	TO
1083	1090	express	express	VB
1091	1095	CD38	cd38	NN
1095	1096	.	.	.

1097	1099	In	in	IN
1100	1108	contrast	contrast	NN
1108	1109	,	,	,
1110	1114	CD38	cd38	NN
1115	1125	expression	expression	NN
1126	1129	was	be	VBD
1130	1133	not	not	RB
1134	1143	inducible	inducible	JJ
1144	1146	by	by	IN
1147	1151	ATRA	ATRA	NNP
1152	1154	in	in	IN
1155	1161	HL-60R	HL-60R	NNP
1162	1167	cells	cell	NNS
1167	1168	,	,	,
1169	1180	transfected	transfecte	VBN
1181	1185	with	with	IN
1186	1187	a	a	DT
1188	1198	functional	functional	JJ
1199	1202	RAR	rar	NN
1203	1207	beta	beta	NN
1207	1208	,	,	,
1209	1212	RAR	RAR	NNP
1213	1218	gamma	gamma	NN
1218	1219	,	,	,
1220	1222	or	or	CC
1223	1226	RXR	RXR	NNP
1227	1232	alpha	alpha	NN
1233	1241	receptor	receptor	NN
1241	1242	.	.	.

1243	1252	Induction	Induction	NNP
1253	1255	of	of	IN
1256	1260	CD38	cd38	NN
1261	1263	in	in	IN
1264	1269	acute	acute	JJ
1270	1283	promyelocytic	promyelocytic	JJ
1284	1287	and	and	CC
1288	1293	acute	acute	JJ
1294	1306	myeloblastic	myeloblastic	JJ
1307	1315	leukemia	leukemia	NN
1316	1321	cells	cell	NNS
1322	1325	was	be	VBD
1326	1337	independent	independent	JJ
1338	1340	of	of	IN
1341	1353	ATRA-induced	atra-induced	JJ
1354	1373	cytodifferentiation	cytodifferentiation	NN
1373	1374	.	.	.

1375	1384	Following	follow	VBG
1385	1392	culture	culture	NN
1393	1397	with	with	IN
1398	1402	ATRA	ATRA	NNP
1402	1403	,	,	,
1404	1413	increased	increase	VBD
1414	1418	CD38	cd38	NN
1419	1426	protein	protein	NN
1427	1433	levels	level	NNS
1434	1438	were	be	VBD
1439	1443	also	also	RB
1444	1452	observed	observe	VBN
1453	1455	in	in	IN
1456	1462	normal	normal	JJ
1463	1468	CD34+	cd34+	JJ
1469	1473	bone	bone	NN
1474	1480	marrow	marrow	NN
1481	1486	cells	cell	NNS
1486	1487	,	,	,
1488	1491	but	but	CC
1492	1495	not	not	RB
1496	1498	on	on	IN
1499	1505	normal	normal	JJ
1506	1517	circulating	circulate	VBG
1518	1530	granulocytes	granulocyte	NNS
1530	1531	.	.	.

1532	1536	From	from	IN
1537	1542	these	these	DT
1543	1550	results	result	NNS
1550	1551	,	,	,
1552	1554	we	we	PRP
1555	1563	conclude	conclude	VBP
1564	1568	that	that	IN
1569	1573	CD38	cd38	NN
1574	1576	is	be	VBZ
1577	1581	ATRA	ATRA	NNP
1582	1591	inducible	inducible	JJ
1592	1594	in	in	IN
1595	1602	myeloid	myeloid	JJ
1603	1611	leukemia	leukemia	NN
1612	1617	cells	cell	NNS
1618	1621	and	and	CC
1622	1628	normal	normal	JJ
1629	1634	CD34+	cd34+	JJ
1635	1639	bone	bone	NN
1640	1646	marrow	marrow	NN
1647	1652	cells	cell	NNS
1652	1653	.	.	.

1654	1658	This	this	DT
1659	1665	effect	effect	NN
1666	1668	is	be	VBZ
1669	1680	independent	independent	JJ
1681	1683	of	of	IN
1684	1699	differentiation	differentiation	NN
1700	1703	and	and	CC
1704	1706	is	be	VBZ
1707	1715	mediated	mediate	VBN
1716	1718	by	by	IN
1719	1722	RAR	rar	NN
1723	1728	alpha	alpha	NN
1729	1731	in	in	IN
1732	1737	HL-60	hl-60	NN
1738	1743	cells	cell	NNS
1743	1744	,	,	,
1745	1755	suggesting	suggest	VBG
1756	1757	a	a	DT
1758	1765	similar	similar	JJ
1766	1770	role	role	NN
1771	1774	for	for	IN
1775	1778	RAR	rar	NN
1779	1784	alpha	alpha	NN
1785	1787	in	in	IN
1788	1792	CD38	cd38	NN
1793	1803	expression	expression	NN
1804	1806	in	in	IN
1807	1812	other	other	JJ
1813	1826	hematopoietic	hematopoietic	JJ
1827	1832	cells	cell	NNS
1832	1833	.	.	.